New Peracetic Acid INAD Expands Treatment Options for Aquaculture Producers
The U.S. Fish and Wildlife Service’s Aquatic Animal Drug Approval Partnership (AADAP) has announced that Peracetic Acid (VIGOROX® Clear) is now available under INAD #14-172 for all freshwater and saltwater fish and shrimp species, including eggs.
The treatment may be used against waterborne pathogens, including bacteria, viruses, parasites, and fungi, in recirculating aquaculture systems (RAS) and pond settings.
Facilities interested in participating must submit a facility-specific effluent table to the FDA and receive approval before using the treatment under the INAD. The availability of this treatment provides another potential tool for producers working to protect fish health, manage disease risks, and strengthen biosecurity practices.
For additional information, contact Bonnie Johnson at bonnie_johnson@fws.gov.
Webinar: National INAD Program and New AQUI-S® E10% FDA Approval
Aquaculture and fisheries professionals are invited to join the U.S. Fish and Wildlife Service’s next Fish and Aquatic Conservation Webinar on December 10, 2026, at 3:00 p.m. EST.
Presented by AADAP’s Bonnie Johnson, the webinar will explore the Aquatic Animal Drug Approval Partnership (AADAP) Program, the National INAD Program, and recent developments in aquatic animal drug approvals.
The presentation will explain how the National INAD Program provides participating facilities with access to investigational fish drugs under FDA-authorized protocols while helping generate the research data needed to support future approvals and expanded drug uses.
One of the featured topics will be the recent FDA approval of AQUI-S® E10%, an immediate-release sedative for wild freshwater finfish used during spawning, tagging, weighing, measuring, and other fisheries management activities.
Attendees will also learn about AADAP research involving sedatives, immersion treatments, medicated feeds, spawning aids, and other tools designed to address aquatic animal health and fisheries management needs.
The webinar is open to anyone interested in aquatic animal health and fisheries or aquaculture management.
REGISTER FOR THE DECEMBER 10 WEBINAR
U.S. Aquatic Animal Health Research Featured at International Symposium
The U.S. Fish and Wildlife Service’s Aquatic Animal Drug Approval Partnership (AADAP) Program was represented at the 10th International Symposium on Aquatic Animal Health, held in September 2026 in Bodø, Norway.
AADAP Branch Manager Guppy Blair presented on the agency’s work to advance aquatic animal drug development and expand access to new medications for aquaculture and fisheries professionals in the United States.
The symposium, themed “The Science and Practice of Fish Health and Welfare—From Physiology to the Farm,” brought together international researchers, government representatives, and industry professionals to share developments in aquatic animal health, fish welfare, and sustainable production.
Blair’s presentation, “The US Fish and Wildlife Service’s Aquatic Animal Drug Approval Partnership Program: Providing New Medications to Aquaculture and Fisheries Professionals in the U.S.,” was delivered during a session addressing current approaches to mitigating antimicrobial resistance (AMR).
AADAP’s continued work on drug approvals, treatment development, and aquatic animal health research is important to the future of U.S. aquaculture and the availability of practical tools for fish producers.